Unity Biotechnology (FRA:9U90) ROE % Adjusted to Book Value : -128.43% (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Unity Biotechnology ROE % Adjusted to Book Value?

Unity Biotechnology's ROE % for the quarter that ended in Dec. 2024 was -340.34%. Unity Biotechnology's PB Ratio for the quarter that ended in Dec. 2024 was 2.65. Unity Biotechnology's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -128.43%.

Unity Biotechnology ROE % Adjusted to Book Value Historical Data

The historical data trend for Unity Biotechnology's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Unity Biotechnology ROE % Adjusted to Book Value Chart

Unity Biotechnology Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-26.77

-65.88

-116.85

-84.92

-58.10

Unity Biotechnology Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-48.72	-79.09	-83.67	-89.42	-128.43

Competitive Comparison of Unity Biotechnology's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Unity Biotechnology's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Unity Biotechnology's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Unity Biotechnology's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Unity Biotechnology's ROE % Adjusted to Book Value falls into.

Save Embed

;

Save Embed

;

Unity Biotechnology ROE % Adjusted to Book Value Calculation

Unity Biotechnology's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-153.96%	/	2.65
	=	-58.10%

Unity Biotechnology's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-340.34%	/	2.65
	=	-128.43%

Unity Biotechnology ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Unity Biotechnology's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Unity Biotechnology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Unity Biotechnology Inc (FRA:9U90) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

UBX:USA 0YC0:UK 9U90:Germany

Address

285 East Grand Avenue, South San Francisco, CA, USA, 94080

Website

https://www.unitybiotechnology.com

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.

Unity Biotechnology Headlines

No Headlines